Sanofi-Aventis’ new obesity drug Acomplia could eventually generate sales of over $3 billion a year, its chairman told Reuters news service yesterday.
“I can tell you that for such a product, in my expectations, three (billion dollars) is not too much,” Jean-Francois Dehecq said during a meeting of pharmaceutical executives in Brussels, commenting on forecasts for the medicine.
Sanofi-Aventis anticipates the launch of Acomplia, which also helps people quit smoking, to take place in the first part of 2006.
The drug is among the world’s most anticipated since a global obesity epidemic threatens the health of millions of people in developed countries.
